LU90097I2 - Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique - Google Patents

Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique

Info

Publication number
LU90097I2
LU90097I2 LU90097C LU90097C LU90097I2 LU 90097 I2 LU90097 I2 LU 90097I2 LU 90097 C LU90097 C LU 90097C LU 90097 C LU90097 C LU 90097C LU 90097 I2 LU90097 I2 LU 90097I2
Authority
LU
Luxembourg
Prior art keywords
ropinirole
optionally
pharmaceutically acceptable
acceptable salts
hydrochloric salt
Prior art date
Application number
LU90097C
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23776840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90097(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of LU90097I2 publication Critical patent/LU90097I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
LU90097C 1982-12-07 1983-11-30 Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique LU90097I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/447,564 US4452808A (en) 1982-12-07 1982-12-07 4-Aminoalkyl-2(3H)-indolones

Publications (1)

Publication Number Publication Date
LU90097I2 true LU90097I2 (fr) 1997-07-16

Family

ID=23776840

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90097C LU90097I2 (fr) 1982-12-07 1983-11-30 Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique

Country Status (27)

Country Link
US (1) US4452808A (fr)
EP (1) EP0113964B1 (fr)
JP (1) JPS59112964A (fr)
KR (1) KR910001042B1 (fr)
AU (1) AU560170B2 (fr)
BR (1) BR1100036A (fr)
CA (1) CA1208650A (fr)
CY (1) CY1497A (fr)
CZ (1) CZ398191A3 (fr)
DE (1) DE3367090D1 (fr)
DK (1) DK156514C (fr)
DZ (1) DZ587A1 (fr)
EG (1) EG16556A (fr)
ES (2) ES527827A0 (fr)
FI (1) FI77849C (fr)
GR (1) GR79121B (fr)
HK (1) HK82089A (fr)
IE (1) IE56347B1 (fr)
IL (1) IL70311A (fr)
LU (1) LU90097I2 (fr)
NL (1) NL970005I2 (fr)
NO (2) NO160135C (fr)
NZ (1) NZ206344A (fr)
PH (1) PH22067A (fr)
PT (1) PT77739B (fr)
ZA (1) ZA839094B (fr)
ZW (1) ZW25883A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4657929A (en) * 1983-10-25 1987-04-14 Fisons Plc Compounds
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8621040D0 (en) * 1986-08-30 1986-10-08 Smith Kline French Lab Process
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
AU4312593A (en) * 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9526511D0 (en) * 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
EP0923551B1 (fr) * 1996-08-27 2002-06-05 American Home Products Corporation Derives de 4-aminoethoxy indolone
AU3555099A (en) * 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
ATE358488T1 (de) * 2002-09-13 2007-04-15 Motac Neuroscience Ltd Behandlung von dyskinesie mit 2,3-benzodiazepinen
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
ES2237307B1 (es) * 2003-10-14 2006-11-01 Urquima, S.A. Procedimiento para la preparacion de ropinirol.
WO2005074387A2 (fr) * 2003-12-30 2005-08-18 Sun Pharmaceutical Industries Limited Nouvelles formes cristallines d'hydrochlorure de 4-[2-di-n-propylamino)ethyl]-2 (3h)- indolone
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
WO2005105741A1 (fr) * 2004-02-11 2005-11-10 Sun Pharmaceutical Industries Limited Hydrochlorure de 4-[2-(di-n-propylamino)ethyl]-2(3h)-indolone sensiblement pur
WO2005080333A1 (fr) * 2004-02-19 2005-09-01 Torrent Pharmaceuticals Ltd Processus de purification de ropinirole
PL1751106T3 (pl) * 2004-05-11 2009-07-31 Egis Gyogyszergyar Nyrt Piperazynowe pochodne alkilooksyindoli
HUP0400953A3 (en) * 2004-05-11 2008-02-28 Egis Gyogyszergyar Nyilvanosan Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
EP1863484A1 (fr) * 2005-03-21 2007-12-12 Pfizer Limited Derives de triazole substitues utilises en tant qu'antagonistes d'oxytocine
CN100457711C (zh) * 2005-06-27 2009-02-04 上海奥博生物医药技术有限公司 2-甲基-3-硝基苯基烷基胺衍生物或其盐的制备方法
WO2007010557A2 (fr) * 2005-07-22 2007-01-25 Ind-Swift Laboratorie Limted Methode de preparation de ropinirole tres pur
US7968731B2 (en) 2006-03-29 2011-06-28 Alembic Limited Process for the purification of Ropinirole hydrochloride
EA017896B1 (ru) 2006-04-06 2013-04-30 Нюпэф Инк. Имплантаты для лечения состояний, ассоциируемых с допамином
US20070254941A1 (en) * 2006-04-21 2007-11-01 Glenmark Pharmaceuticals Limited Subtantially pure ropinirole hydrochloride, polymorphic form of ropinirole and process for their preparation
CN100457732C (zh) * 2006-05-25 2009-02-04 药源药物化学（上海）有限公司 罗匹尼罗的制备方法
WO2008001204A2 (fr) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
ATE535243T1 (de) * 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
US20090076124A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ropinirole
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
WO2010023693A2 (fr) * 2008-09-01 2010-03-04 Lupin Limited Nouvelles compositions de ropinirole à libération contrôlée
EP2452677A1 (fr) 2008-09-29 2012-05-16 Wockhardt Limited Forme posologique à libération prolongée de ropinirole
WO2010060070A2 (fr) * 2008-11-24 2010-05-27 Auspex Pharmaceuticals, Inc. Modulateurs à base d'indolinone du récepteur de la dopamine
EP2438917B1 (fr) 2009-05-21 2014-09-03 Hisamitsu Pharmaceutical Co., Inc. Préparation transdermique
WO2011072704A1 (fr) * 2009-12-16 2011-06-23 Pharmathen S.A. Procédé de préparation de ropinirole et de ses sels
MY153762A (en) 2010-04-30 2015-03-13 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
CN101891641B (zh) * 2010-07-27 2015-06-10 北京华禧联合科技发展有限公司 盐酸罗匹尼罗关键中间体的稳定形态及其制备
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
WO2012129429A2 (fr) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
BR112015007872A2 (pt) 2012-11-02 2017-07-04 Teikoku Pharma Usa Inc composições transdermais de propinilaminoindano
WO2014092006A1 (fr) 2012-12-10 2014-06-19 キッセイ薬品工業株式会社 Nouveau dérivé d'octahydropyridoquinazoline, composition pharmaceutique le contenant, et utilisations pour ledit dérivé et ladite composition
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
WO2018227553A1 (fr) 2017-06-16 2018-12-20 浙江华海立诚药业有限公司 Procédé de purification de chlorhydrate de ropinirole
CN115466209A (zh) * 2022-09-29 2022-12-13 南通大学 一种罗匹尼罗环戊烷并吲哚酮杂质的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA895875A (en) * 1972-03-21 Bourdais Jacques Mercapto indole derivatives
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
JPS5825673B2 (ja) * 1976-03-31 1983-05-28 大塚製薬株式会社 オキシインド−ル誘導体
JPS5840539B2 (ja) * 1976-03-31 1983-09-06 大塚製薬株式会社 α−置換アミノアルカノイルオキシインド−ル誘導体
JPS5919537B2 (ja) * 1976-08-02 1984-05-07 大塚製薬株式会社 オキシインド−ル誘導体
US4317944A (en) * 1980-08-15 1982-03-02 General Electric Company Preparation of 2,2-bis(4-hydroxyphenyl) propane
US4314944A (en) * 1980-08-22 1982-02-09 Smithkline Corporation 4-Aminoalkyl-7-hydroxy-2(3H)-indolones

Also Published As

Publication number Publication date
IE56347B1 (en) 1991-07-03
AU2158583A (en) 1984-06-14
NO1999011I1 (no) 1999-06-18
NL970005I2 (nl) 1997-10-01
CA1208650A (fr) 1986-07-29
GR79121B (fr) 1984-10-02
ZW25883A1 (en) 1984-04-18
DE3367090D1 (de) 1986-11-27
FI77849C (fi) 1989-05-10
JPS59112964A (ja) 1984-06-29
FI834421A (fi) 1984-06-08
CZ398191A3 (en) 1993-02-17
DZ587A1 (fr) 2004-09-13
ES8600239A1 (es) 1985-10-01
DK562183A (da) 1984-06-08
NO160135B (no) 1988-12-05
JPH0150703B2 (fr) 1989-10-31
DK562183D0 (da) 1983-12-06
IE832866L (en) 1984-06-07
IL70311A0 (en) 1984-02-29
FI834421A0 (fi) 1983-12-02
NO160135C (no) 1989-03-15
EP0113964A1 (fr) 1984-07-25
DK156514B (da) 1989-09-04
EG16556A (en) 1989-01-30
ES8604143A1 (es) 1986-01-16
NZ206344A (en) 1987-03-31
ES543593A0 (es) 1986-01-16
PT77739A (en) 1983-12-01
NO834485L (no) 1984-06-08
PH22067A (en) 1988-05-20
BR1100036A (pt) 2000-01-11
HK82089A (en) 1989-10-20
PT77739B (en) 1986-03-27
NL970005I1 (nl) 1997-04-01
AU560170B2 (en) 1987-04-02
US4452808A (en) 1984-06-05
ES527827A0 (es) 1985-10-01
IL70311A (en) 1986-11-30
FI77849B (fi) 1989-01-31
CY1497A (en) 1990-02-16
KR910001042B1 (ko) 1991-02-21
EP0113964B1 (fr) 1986-10-22
KR840006963A (ko) 1984-12-04
DK156514C (da) 1990-03-12
ZA839094B (en) 1985-02-27

Similar Documents

Publication Publication Date Title
LU90097I2 (fr) Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique
LU90593I2 (fr) Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU88809I2 (fr) Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU90426I2 (fr) Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU88746I2 (fr) Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
BE875890A (fr) Enlevement d'impuretes sous forme de parties par milliard de saumures alcalines
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU88797I2 (fr) Raltitrexed et ses sels esters et hydrates pharmaceutiquement acceptables
LT2274B (lt) Benzimidazolo dariniu arba ju drusku gavimo budas
EP0278173A3 (en) Use of heterocyclic derivatives in the treatment of depressions
LU92564I2 (fr) Médocaril de ceftobiprole et les sels pharmaceutiquement acceptables qui en dérivent
FI913524A (fi) Med vattenhaltigt zein belagda soetningsmedel och andra ingredienser foer tuggummi.
IT8620298A0 (it) Sali di diacetilreina e loro impiego terapeutico nel trattamento dell'artrosi.
FR2602421B1 (fr) Composition sous forme de gel pour induire et stimuler la croissance des cheveux et diminuer leur chute a base de derives de piperidino-pyrimidine
ES537312A0 (es) Procedimiento para la desintegracion de derivados de s-triacin en soluciones acuosas
FR2609391B1 (fr) Preparations pharmaceutiques sous forme de suppositoires bioadhesifs
ITRM910026A0 (it) Generatore di acqua dolce
LU88574I2 (fr) CEFEPIME et ses sels pharmaceutiquement acceptables (Maxipime R)
DK670087D0 (da) Apparat til brug ved afskaering af fisks hoveder
DK497088A (da) Vandoploeselige polysakkarider samt fremstilling og anvendelse deraf
FR2542197B1 (fr) Remede medicamenteux et prophylactique anticarie dentaire sous forme de granules
LU90070I2 (fr) Zafirlukast optionnellement sous forme d'un sel de celui-ci